Clinical trial • Phase III • Other
AD-700 for Metabolic dysfunction
Phase III trial of AD-700 for Metabolic dysfunction. 21 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Metabolic dysfunction
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 14-02-2025
- First CTIS Authorization Date
- 05-05-2025
Trial design
Phase III trial across 2 sites in Finland.
- Target Sample Size
- 21
Eligibility
Recruits 21 No vulnerable populations selected. Population: Healthy volunteers. No consent/assent details provided..
- Vulnerable Population
- No vulnerable populations selected. Population: Healthy volunteers. No consent/assent details provided.
Recruitment
- Planned Sample Size
- 21
- Recruitment Window Months
- 17
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 21
Finland
- Earliest CTIS Part Ii Submission Date
- 17-04-2025
- Latest Decision Or Authorization Date
- 12-03-2026
- Processing Time Days
- 329
- Number Of Sites
- 2
- Number Of Participants
- 21
Sites
- Site Name
- CRST Helsinki Oy
- Contact Person Name
- Max Kiugel
- Contact Person Email
- max.kiugel@crst.fi
- Site Name
- Clinical Research Services Turku CRST Oy
- Contact Person Name
- Max Kiugel
- Contact Person Email
- max.kiugel@crst.fi
Sponsor
Primary sponsor
- Full Name
- Adiposs S.A.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Investigational products
- Investigational Product Name
- AD-700
- Routes Of Administration
- oral
- Route
- oral
Related trials
Other published trials that may interest you.